Solid Biosciences reports improved pulmonary function in DMD gene therapy trial, controls decline

Solid Biosciences Inc.

PEF % predicted improved in all 4 evaluable dosed patients (+2.5% to +38.5%); 2 evaluable controls declined (-1.1%, -18.2%) at one year.
FEV1 % predicted improved in all 5 evaluable dosed patients (+2.8% to +15.5%); all 3 evaluable controls declined (-8.7% to -17.0%).
Data from first 6 patients in Phase I/II IGNITE DMD trial of SGT-001; presented at Child Neurology Society 50th Annual Meeting.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.